Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Neurology
Disease Category: Migraine and Cluster Headaches
Trial Information
Acute treatment of Migraine when administered during the Moderate-Severe Pain Phase of the Migraine
Research study for patients suffering with migraines who have an active prescription for a butalbital-containing medication.
Patient Inclusion Criteria:
- Male or Female
- 18-65
- Active Butalbital containing medication prescription, that has been used within the past 30 days.
- Migraines with or without aura.
- At least 2 attacks per month.
- Able to perform testing on a electronic diary.
- Sign a informed consent for treatment.
Patient Exclusion Criteria:
- More than 8 migraines per month.
- Have taken butalbital containing medication daily.
- A history of any medical condition other than migraines.
Primary Outcomes: The main purpose of this study is to compare the effectiveness of TREXIMA and Fioricet in helping to control symptoms of acute migraine when administered during the moderate to severe pain phase of a migraine.
Key Secondary Outcomes: The safety and tolerability of TREXIMA will be compared to the safety and tolerability of Fioricet. About 500 subjects with migraine who are between 18 and 65 years old will be in the study
Rosemary Kenitz, Coordinator
Schenectady Neurological Consultants, PC
1401 Union Street
Schenectady, NY 12308
Phone: 518-381-9202
Fax: 518-381-1182
EMail: neuroresearch1401@yahoo.com
View Google Map
If you would like to learn more about participating in this study, please send an e-mail message using the form below.
DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the
clinical trials industry. The information provided in this service is designed
to help patients find clinical trials that may be of interest to them, and to
help patients contact the centers conducting the research. CenterWatch is
neither promoting this research nor involved in conducting any of these
trials.
